# A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).

> **NCT07234773** · PHASE1 · RECRUITING · sponsor: **Kali Therapeutics, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** KT501

## Key facts

- **NCT ID:** NCT07234773
- **Lead sponsor:** Kali Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-06
- **Primary completion:** 2027-02
- **Final completion:** 2027-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234773, "A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT07234773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*